Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0HWAWD
ADC Name	Zapadcine-1
Synonyms	Zapadcine 1; DR5 mAb-Py-VC-PAB-MMAD Click to Show/Hide
Drug Status	Investigative
Indication	In total 3 Indication(s) Acute lymphocytic leukemia [ICD11:2B33] Investigative Lung cancer [ICD11:2C25] Investigative Mature T-cell lymphoma [ICD11:2A90] Investigative
Drug-to-Antibody Ratio	4
	3D MOL	2D MOL
Antibody Name	Zaptuzumab		Antibody Info
Antigen Name	Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)		Antigen Info
Payload Name	Monomethyl auristatin D		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	PY-VC-PABC		Linker Info
Conjugate Type	ThioBridge technology, site-specific conjugation through reduced inter-chain cysteines.

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 100	%	Jurkat E6.1 cells	Leukemia

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 14)	Positive DR5 expression (DR5+++/++)
Method Description	Zapadcine-1 (9 mg/kg, Q3D3, every three days for 3 times) induces efficient tumor cell killing in cell line-derived models of Jurkat E6-1 cells with DR5 expression with high expression.
In Vivo Model	Jurkat E6.1 CDX model
In Vitro Model	Leukemia	Jurkat E6.1 cells		CVCL_0367

References

Ref 1	A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors. Theranostics. 2019 Jul 13;9(18):5412-5423. doi: 10.7150/thno.33598. eCollection 2019.